Table 1 Patients’ characteristics at baseline and after lenalidomide treatment.
Characteristics | N = 99 |
|---|---|
Baseline variables | |
Gender, n (%) | |
Male | 22 (22%) |
Female | 77 (78%) |
Age* | 73 (47–89) |
Hemoglobin (gr/dl)* | 8.50 (6.50–12.30) |
Absolute neutrophil counts (109/L)* | 2.00 (0.20–7.80) |
Platelets (x109/L)* | 305 (28–1,411) |
Bone marrow blasts (%)* | 2.00 (0–19) |
Erythroid Dysplasia, n (%) | 91 (97%) |
Megakaryocytic Dysplasia, n (%) | 75 (80%) |
5q isolated, n (%) | 87 (91%) |
IPSS-R score^, n (%) | |
Very Low | 2 (2.4%) |
Low | 47 (57%) |
Intermediate | 30 (37%) |
High | 3 (3.6%) |
WHO 2016 diagnosis&, n (%) | |
MDS with isolated del(5q) | 89 (89.9%) |
MDS-EB-1 | 8 (8.1%) |
MDS-EB-2 | 2 (2.0%) |
Erythropoietin (mU/mL)* | 186 (10–941) |
Mean corpuscular volume (fL)* | 107 (75–226) |
Lactate dehydrogenase (U/L)* | 275 (139–673) |
Creatinine (mg/dL)* | 0.90 (0.40–2.20) |
Red Blood Cells Transfusion burden, n (%) | |
<4 units/8 weeks | 49 (50%) |
≥4 units/8 weeks | 49 (50%) |
Post-treatment variables | |
Cytogenetic Response, n (%) | |
No response | 16 (21%) |
Partial | 19 (26%) |
Complete | 39 (53%) |
Erythroid Response, n (%) | 84 (85%) |
Transfusion independence, n (%) | 77 (80%) |
Neutropenia (<1 × 109/L) during first 2 cycles, n (%) | 47 (51%) |
Thrombocytopenia (<100 × 109/L) during first 2 cycles, n (%) | 30 (33%) |
Total N. cycles of Lenalidomide* | 21 (2–131) |
Secondary solid tumor, n (%) | 6 (6.1%) |
